Drug intelligence / Profile preview

PX019

Development stage: Preclinical
Lead developer: Pannex Therapeutics
Modality: Small Molecules
Administration: Parenteral

Overview

PX019 is a small molecule inhibitor of the Pannexin 1 (Panx1) channel, currently under development by Panex (Pannexin Therapeutics) as a lead candidate for oncology indications. Pannexin 1 is a membrane protein that forms large-pore channels involved in the release of ATP and other signaling molecules, playing a significant role in tumor progression, metastasis, and the tumor microenvironment. By blocking Panx1, PX019 aims to disrupt these pro-tumorigenic signaling pathways. It is currently in the preclinical stage of development.

Targets

PANX1 (Pannexin-1)

Beyond the preview

Go deeper on PX019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PX019.

Explore the full profile